Literature DB >> 20539094

Using highly active antiretroviral therapy to decrease perioperative HIV-1 transmission risk.

Adam M Spivak, Robert F Siliciano.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20539094      PMCID： PMC4509634          DOI： 10.1097/QAD.0b013e32832f3155

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  6 in total

1.  Preoperative use of raltegravir-containing regimen as induction therapy: very rapid decline of HIV-1 viral load.

Authors:  Stephan Gerardus Papendorp; Guido E van den Berk
Journal:  AIDS       Date:  2009-03-27       Impact factor: 4.177

2.  HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase.

Authors:  A S Espeseth; P Felock; A Wolfe; M Witmer; J Grobler; N Anthony; M Egbertson; J Y Melamed; S Young; T Hamill; J L Cole; D J Hazuda
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

3.  Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier.

Authors:  Inge Dierynck; Mieke De Wit; Emmanuel Gustin; Inge Keuleers; Johan Vandersmissen; Sabine Hallenberger; Kurt Hertogs
Journal:  J Virol       Date:  2007-10-10       Impact factor: 5.103

4.  Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study.

Authors:  Martin Markowitz; Bach-Yen Nguyen; Eduardo Gotuzzo; Fernando Mendo; Winai Ratanasuwan; Colin Kovacs; Guillermo Prada; Javier O Morales-Ramirez; Clyde S Crumpacker; Robin D Isaacs; Lucinda R Gilde; Hong Wan; Michael D Miller; Larissa A Wenning; Hedy Teppler
Journal:  J Acquir Immune Defic Syndr       Date:  2007-10-01       Impact factor: 3.731

5.  Decay dynamics of HIV-1 depend on the inhibited stages of the viral life cycle.

Authors:  Ahmad R Sedaghat; Jason B Dinoso; Lin Shen; Claus O Wilke; Robert F Siliciano
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-24       Impact factor: 11.205

6.  Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.

Authors:  David A Cooper; Roy T Steigbigel; Jose M Gatell; Jurgen K Rockstroh; Christine Katlama; Patrick Yeni; Adriano Lazzarin; Bonaventura Clotet; Princy N Kumar; Joseph E Eron; Mauro Schechter; Martin Markowitz; Mona R Loutfy; Jeffrey L Lennox; Jing Zhao; Joshua Chen; Desmond M Ryan; Rand R Rhodes; John A Killar; Lucinda R Gilde; Kim M Strohmaier; Anne R Meibohm; Michael D Miller; Daria J Hazuda; Michael L Nessly; Mark J DiNubile; Robin D Isaacs; Hedy Teppler; Bach-Yen Nguyen
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.